[go: up one dir, main page]

James et al., 2018 - Google Patents

Detection of residual proteins UL5 and UL29 using a targeted proteomics approach in HSV529, a replication-deficient HSV-2 vaccine candidate

James et al., 2018

Document ID
10312615502515884426
Author
James D
Fradin M
Pedyczak A
Carpick B
Publication year
Publication venue
Journal of Pharmaceutical Sciences

External Links

Snippet

HSV529 is a replication defective human herpes simplex virus (HSV)–2 viral vaccine candidate in clinical development. An engineered cell line is required to support production of HSV529 by transgenic expression of the HSV-1 transcription factors UL5 (HELI) and UL29 …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/558—Immunoassay; Biospecific binding assay using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
Kang et al. LC–MS bioanalysis of intact proteins and peptides
Whiteaker et al. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers
Rathore et al. The role of mass spectrometry in the characterization of biologic protein products
Heudi et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC− MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry
Becker et al. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC–MS/MS
Mills et al. Detecting monoclonal immunoglobulins in human serum using mass spectrometry
Whiteaker et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry
Jian et al. A workflow for absolute quantitation of large therapeutic proteins in biological samples at intact level using LC-HRMS
Xu et al. A multiplexed hybrid LC–MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study
Li et al. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC–MS
Griffin et al. Abundance ratio-dependent proteomic analysis by mass spectrometry
Zhang et al. Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P‐glycoprotein in various biological samples
Lietz et al. Large-scale collision cross-section profiling on a traveling wave ion mobility mass spectrometer
Rafalko et al. Development of a Chip/Chip/SRM platform using digital chip isoelectric focusing and LC-Chip mass spectrometry for enrichment and quantitation of low abundance protein biomarkers in human plasma
Chen et al. A highly sensitive LC-MS/MS method for targeted quantitation of lipase host cell proteins in biotherapeutics
Sugimoto et al. Perspectives on potentiating immunocapture-LC–MS for the bioanalysis of biotherapeutics and biomarkers
Hessmann et al. Host cell protein quantification workflow using optimized standards combined with data-independent acquisition mass spectrometry
Li et al. Analytical performance evaluation of identity, quality-attribute monitoring and new peak detection in a platform multi-attribute method using Lys-C digestion for characterization and quality control of therapeutic monoclonal antibodies
US20230349903A1 (en) Assays and reagents for characterization of mhci peptide binding
Long et al. Simultaneous quantification of spike and nucleocapsid protein in inactivated COVID-19 vaccine bulk by liquid chromatography-tandem mass spectrometry
Ji et al. A highly sensitive and robust LC-MS platform for host cell protein characterization in biotherapeutics
James et al. Detection of residual proteins UL5 and UL29 using a targeted proteomics approach in HSV529, a replication-deficient HSV-2 vaccine candidate
Carvalho et al. SWATH-MS as a strategy for CHO host cell protein identification and quantification supporting the characterization of mAb purification platforms
US20140156206A1 (en) Detection and Quantification of Polypeptides Using Mass Spectrometry
Yao et al. LC-MS differential analysis for fast and sensitive determination of biotransformation of therapeutic proteins